
U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.



NRC FORM 374A	U.S. NUCLEAR REGULATORY COMMISSION		PAGE 2 OF 4 PAGES
	License No.: 07-17792-01	Docket or Reference No.:	
MATERIALS LICENSE		030-13331	
SUPPLEMENTARY SHEET	Amendment No. 55		

CONDITIONS

- 10. A. Licensed material may be used or stored at the licensee's facilities located at 424 Savannah Road, Lewes, Delaware.
 - B. Licensed material listed in Subitem No. 6.B. may be used or stored at the licensee's facilities located at Beebe Health Campus, Bookhammer Outpatient Center, 18941 John J. Williams Highway (Route 24), Rehobeth Beach, Delaware.
- 11. The Radiation Safety Officer for this license is Lisa Marie Genovese, DMP.
- 12. Licensed material shall only be used by, or under the supervision of:
 - A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.

B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized Users	Material and Use
Georges Abdul-Karim Dahr, M.D.	10 CFR 35.200
Ramon Alberto Rosa, M.D.	10 CFR 35.200
Ellen Bahtiaran, M.D.	10 CFR 35.100,10 CFR 35.200,10 CFR 35.300
Steven R. Chmielewski, M.D.	10 CFR 35.100,10 CFR 35.200,10 CFR 35.300
Brian Costleigh, M.D.	10 CFR 35.300
Andrew Dahlke, M.D.	10 CFR 35.100,10 CFR 35.200
Barry S. Denenberg, M. D.	10 CFR 35.200
Frances Esposito, M.D.	10 CFR 35.100,10 CFR 35.200,10 CFR 35.300
Dennis Michael Flamini, D.O.	10 CFR 35.100,10 CFR 35.200; 10 CFR 35.300, limited to the oral administration of sodium iodide I-131
Mouhanad K. Freih, M. D.	10 CFR 35.100,10 CFR 35.200
Kimberly Gardner, M. D.	10 CFR 35.100,10 CFR 35.200; 10 CFR 35.300, limited to the oral administration of sodium iodide I-131

NRC FORM 374A	U.S. NUCLEAR REGULATORY COMMISSION		PAGE 3 OF 4 PAGES
	License No.: 07-17792-01	Docket or Reference No.:	
MATERIALS LICENSE		030-13331	
SUPPLEMENTARY SHEET	Amendment No. 55		

<u>Authorized Users</u> <u>Material and Use</u>

Jeffrey McCann, M.D. 10 CFR 35.100,10 CFR 35.200

Rajinder Prasad, M.D. 10 CFR 35.200 R KEGU

Michael Ramjattansingh, M.D. 10 CFR 35.100,10 CFR 35.200

- 13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
- 14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
 - A. Letter dated January 20, 2011, except shielding assessment [ML110200525]
 - B. Letter dated February 7, 2011 [ML110390314]
 - C. Facility diagrams received March 19, 2012 [ML120790362]
 - D. Application dated December 18, 2013 [ML14014A072]
 - E. Letter dated May 29, 2014 [ML14163A664]
 - F. Letter dated July 21, 2017 [ML17236A325]
 - G. Letter dated February 14, 2018 [ML18058A586]

NRC FORM 374A	U.S. NUCLEAR REGULATORY COMMISSION		PAGE 4 OF 4 PAGES
	License No.: 07-17792-01	Docket or Reference No.:	
MATERIALS LICENSE		030-13331	
SUPPLEMENTARY SHEET	Amendment No. 55		

- H. Letter dated January 13, 2021 [ML21034A146]
- I. Letter dated January 20, 2021 [ML21049A249]
- J. Letter dated February 5, 2021 [ML21049A254]



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: July 8, 2021 By:	
------------------------	--

Penny Lanzisera Region 1